How it Works

What is the science behind this blood test?

For more details about our cancer blood test, ONCOblot®, please read the following publication about Cancer Prevention:
Cancer Prevention 2012 publication (click to download)

What is this blood test based on?

The ONCOblot® blood test identifies a specific type of protein in the blood, ENOX2, which exists only on the surface of a malignant cancer cell. The ENOX2 proteins are shed into the circulation and can be detected in the blood. These proteins serve as highly sensitive markers for early detection in both primary and recurrent cancer. The test is a valuable complement to early intervention.

How sensitive is this blood test?

The ONCOblot® Test will detect a cancer of 2 million cells compared to 4.5 trillion cells for a positive mammogram.

How does this blood test determine organ site?

The ONCOblot® Test uses techniques known as two-dimensional gel electrophoresis and western blot analysis along with an ENOX2 protein-specific antibody for detection. The result of the blood test is presented visually on the ONCOblot®. Each type of ENOX2 has a specific location (molecular weight and isoelectric point) on the blot to demonstrate ENOX2 presence and to identify the tissue of origin.

In the example below, the circled spot indicates a lung cancer-specific ENOX2 protein. (The two spots labeled R are references used for calibration.)

Actual ONCOblot℠ Result.

What are the steps involved for the ONCOblot® Test?

• Test kit delivered to physician
• Blood draw and test kit completed and sent to ONCOblot® Labs
• Approximately 15 business days
• Results sent to physician

How is the ONCOblot® Test being used?

• Initial screening of patient
• Recurrent cancer testing
• Familial cancer testing
• Screening after completion of cancer treatments

Laboratory-Developed Test (LDT)

ONCOblot® is a laboratory developed, CLIA Accredited, CAP Accredited, blood serum test that meets current FDA guidelines.

Trial Results for Early Detection

Midcourse evaluation in November 2011 of 100 subjects enrolled in an early detection trial revealed the following trends:

• Of 92 subjects presenting with no clinical symptoms, 56 subjects or 60% were negative in the ONCOblot® test.
• Of the same 92 subjects presenting with no clinical symptoms, 36 subjects or 40% were positive in the ONCOblot® test. This aligns with current data of 1 in every 3 individuals is expected to contract cancer in their lifetime.
• Of the 36 subjects with markers testing positive for early stage cancer, 12 were identified as non-small cell lung cancer, 7 as breast cancer, 6 as lymphoma/leukemia, 1 each for ovarian, melanoma, prostate and colon, and 7 having transcript variants not yet in the database.

© 2014 ONCOblot Labs. All Rights Reserved.